Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATOS Atossa Genetics

Trading 02-24 11:47:03 EST

4.08

+0.12

+3.03%

High4.27	Low4.01	Vol35.26K
Open4.01	D1 Closing3.96	Amplitude6.57%
Mkt Cap35.13M	Tradable Cap35.12M	Total Shares8.61M
T/O145.65K	T/O Rate0.41%	Tradable Shares8.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATOS","market":"US","secType":"STK","nameCN":"Atossa Genetics","latestPrice":4.08,"timestamp":1771951459361,"preClose":3.96,"halted":0,"volume":35261,"delay":0,"changeRate":0.03030303030303033,"floatShares":8606660,"shares":8611428,"eps":-3.522115,"marketStatus":"Trading","change":0.12,"latestTime":"02-24 11:47:03 EST","open":4.01,"high":4.27,"low":4.01,"amount":145645.172629,"amplitude":0.065657,"askPrice":4.11,"askSize":200,"bidPrice":4.06,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-3.522115,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771966800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1352350800000,"exchange":"NASDAQ","adjPreClose":3.96,"preHourTrading":{"tag":"盘前","latestPrice":4.02,"preClose":3.96,"latestTime":"09:16 EST","volume":18,"amount":71.9169966,"timestamp":1771942575058,"change":0.06,"changeRate":0.015152,"amplitude":0.036111},"postHourTrading":{"tag":"盘后","latestPrice":3.96,"preClose":3.96,"latestTime":"19:55 EST","volume":84,"amount":338.987,"timestamp":1771894552322,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.225043,"impliedVol":1.366,"impliedVolPercentile":0.688},"requestUrl":"/m/hq/s/ATOS","defaultTab":"news","newsList":[{"id":"2613297697","title":"Atossa Therapeutics:  Entered Into at Market Offering Agreement to Sell Shares Our Common Stock of up to $50,000,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2613297697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613297697?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:18","pubTimestamp":1771622325,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nFWN3ZG112:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2610953582","title":"BRIEF-Atossa Therapeutics Issues Letter To Shareholders Highlighting 2025 Accomplishments And 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2610953582","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610953582?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:58","pubTimestamp":1770818307,"startTime":"0","endTime":"0","summary":"BRIEF-Atossa Therapeutics Issues Letter To Shareholders Highlighting 2025 Accomplishments And 2026 OutlookFeb 11 (Reuters) - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS ISSUES LETTER TO SHAREHO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA40SL1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2610495854","title":"Atossa Therapeutics Completes Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2610495854","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610495854?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:31","pubTimestamp":1770816665,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. has completed a reverse stock split, effective February 2, 2026. The move is intended to help the company regain compliance with Nasdaq listing requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on February 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLc87dWQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2610379958","title":"Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2610379958","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610379958?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:30","pubTimestamp":1770816601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA40SL1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2609396463","title":"Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Terns Pharmaceuticals (TERN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609396463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609396463?lang=en_us&edition=fundamental","pubTime":"2026-02-05 00:10","pubTimestamp":1770221418,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atossa Therapeutics (ATOS – Research Report) and Ter...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-atossa-therapeutics-atos-terns-pharmaceuticals-tern-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-atossa-therapeutics-atos-terns-pharmaceuticals-tern-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4112","BK4139","LU0128526141.USD","BK4007","XBI","LU0320765992.SGD","LU0109394709.USD","ATOS","BK4585","LABU","BK4539","BK4581","LU0029874061.USD","BK4137","TERN","BK4588","LU0889565916.HKD"],"gpt_icon":0},{"id":"2608421851","title":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 03:58 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2608421851","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608421851?lang=en_us&edition=fundamental","pubTime":"2026-02-02 16:58","pubTimestamp":1770022681,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 03:58 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nAQN2LKAQ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2607786190","title":"Atossa Genetics trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2607786190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607786190?lang=en_us&edition=fundamental","pubTime":"2026-01-31 08:50","pubTimestamp":1769820613,"startTime":"0","endTime":"0","summary":"19:50 EST Atossa Genetics trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking financ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atossa-genetics-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atossa-genetics-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2606481072","title":"Atossa Therapeutics - Board Approves Reverse Stock Split at 15:1 Ratio - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2606481072","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606481072?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:05","pubTimestamp":1769432713,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YP07P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2606324897","title":"Atossa Therapeutics Announces 15-for-1 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2606324897","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606324897?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:02","pubTimestamp":1769432540,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. has announced a 15-for-1 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on February 2, 2026. The company's shares will begin trading on a split-adjusted basis under a new CUSIP number, while continuing to trade on Nasdaq under the symbol \"ATOS.\" Fractional shares will not be issued; instead, cash will be paid for any fractional entitlements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 26, 2026, and is solely responsible for the information contained t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDLcgTWx3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2605488340","title":"Atossa Therapeutics' Founder and CEO Steven Quay, M.d., Ph.d. Named One of the Top 50 Healthcare Technology Ceos of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2605488340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605488340?lang=en_us&edition=fundamental","pubTime":"2026-01-21 22:05","pubTimestamp":1769004301,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUA679FQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2604912536","title":"Stocks to Watch: Atossa Therapeutics, Union Pacific","url":"https://stock-news.laohu8.com/highlight/detail?id=2604912536","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604912536?lang=en_us&edition=fundamental","pubTime":"2026-01-17 07:14","pubTimestamp":1768605240,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics said the FDA gave an orphan drug designation to its drug Z-Endoxifen to treat Duchenne muscular dystrophy. Shares gained 16% to 71 cents in after-hours trading Friday.A U.S. railroad regulator asked Union Pacific and Norfolk Southern to revise and resubmit their application to merge. Union Pacific's stock rose 4.2% to $239.18 after the bell.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1303367103.USD","LENZ","LU0320765646.SGD","IE00BLSP4452.SGD","ATOS","LU2098885051.SGD","BK4007","LU0820561818.USD","BK4532","LU2463526074.USD","LU1551013342.USD","LU1894683264.USD","LU0738911758.USD","BK4016","LU0820561909.HKD","BK4585","LU0124384867.USD","BK4588","LU0689472784.USD","IE00BMG7P926.USD","LU0354030511.USD","UNP","IE00BMG7P694.USD","LU2360107325.USD","LU0661504455.SGD","IE00BBT3K403.USD","IE00BLSP4239.USD","LU2275660780.HKD","IE00B29SXK94.USD","LU0943347566.SGD","LU1978683503.SGD","IE00BMG7P587.USD","IE00BD4GTT62.SGD","BK4139","BK4539","LU0868494617.USD","LU0949170772.SGD","LU1894683348.USD","IE00BD4GTV84.USD","LU1929549753.HKD","LU0302445910.USD","LU0354030438.USD","BK4534","LU0048573561.USD","LU0820562030.AUD","LU0312595415.SGD","IE00BD4GTW91.USD","LU1861219969.SGD","LU1162221912.USD","IE00B29SXL02.USD"],"gpt_icon":0},{"id":"2604911313","title":"Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2604911313","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604911313?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:40","pubTimestamp":1768599600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nTUA94VZ2T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2603955522","title":"FDA grants Atossa Therapeutics orphan drug designation for (Z)-endoxifen","url":"https://stock-news.laohu8.com/highlight/detail?id=2603955522","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603955522?lang=en_us&edition=fundamental","pubTime":"2026-01-16 10:40","pubTimestamp":1768531218,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics (ATOS)’ (Z)-endoxifen was granted FDA orphan designation as a treatment of Duchenne muscular dystrophy, according to a post to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-grants-atossa-therapeutics-orphan-drug-designation-for-z-endoxifen-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-grants-atossa-therapeutics-orphan-drug-designation-for-z-endoxifen-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","Z","ATOS","BK4539","BK4551","BK4585","BK4548","BK4588","BK4079","BK4139"],"gpt_icon":0},{"id":"2601093818","title":"BRIEF-Atossa Therapeutics Receives FDA \"Study May Proceed\" Letter For (Z)-Endoxifen","url":"https://stock-news.laohu8.com/highlight/detail?id=2601093818","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601093818?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:12","pubTimestamp":1767708771,"startTime":"0","endTime":"0","summary":"BRIEF-Atossa Therapeutics Receives FDA \"Study May Proceed\" Letter For (Z)-Endoxifen Jan 6 (Reuters) - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS RECEIVES FDA \"STUDY MAY PROCEED\" LETTER FOR (Z)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA2FKRGC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2601972758","title":"FDA Clears Atossa Therapeutics to Proceed with (Z)-Endoxifen Trial for Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601972758","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601972758?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:15","pubTimestamp":1767705329,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. has received a \"Study May Proceed\" letter from the U.S. Food and Drug Administration  for its investigational new drug application of -endoxifen for metastatic breast cancer. This regulatory milestone allows Atossa to advance clinical studies of -endoxifen, a selective estrogen receptor modulator/degrader  with a distinct safety profile and pharmacology from tamoxifen. The company is evaluating the drug’s potential in treating metastatic ER+/HER2- breast cancer, including cases resistant to other endocrine therapies. Atossa’s -endoxifen is not yet approved for any indication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief v","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL46cVHM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2601897472","title":"Atossa Therapeutics Receives FDA \"Study May Proceed\" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897472?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:15","pubTimestamp":1767705300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA2FKRGC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2591987649","title":"Atossa Therapeutics Reports Promising (Z)-Endoxifen Trial Results for Breast Cancer Treatment and Risk Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2591987649","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591987649?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:01","pubTimestamp":1765803693,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc., a clinical-stage biopharmaceutical company, presented four clinical trial updates related to its investigational drug -endoxifen at the 2025 San Antonio Breast Cancer Symposium , held December 9-12, 2025. The presentations included initial results from the RECAST DCIS multicenter platform trial, which is evaluating active surveillance and novel endocrine therapy agents for the management of ductal carcinoma in situ . Early pharmacodynamic data indicated that 86% of patients achieved a Week 4 Ki-67 ≤10%, supporting the selection of 40 mg -endoxifen with ovarian function suppression for Phase II studies. The trial is also assessing whether short-term endocrine therapy combined with MRI response assessment can identify DCIS patients suitable for long-term active surveillance and potentially avoid surgery. The findings showed promising antiproliferative efficacy, good tolerability, and steady enrollment, with many patients choosing to continue active surveillance.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL5sGPs7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2591846146","title":"Atossa Therapeutics Inc. Announces Date for Upcoming Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2591846146","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591846146?lang=en_us&edition=fundamental","pubTime":"2025-12-13 06:01","pubTimestamp":1765576888,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. has announced that it will hold a Special Meeting of Stockholders virtually on January 20, 2026. During the meeting, stockholders will be asked to approve a reverse stock split intended to increase the per share trading price of the company's common stock and help maintain its listing on the Nasdaq Stock Market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL4dvmpH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2590543348","title":"Why Are Shares Of Atossa Therapeutics Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590543348","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590543348?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:26","pubTimestamp":1765473960,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/Pharmacy--Pills-And-Tablet-With-Hands-Of.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/Pharmacy--Pills-And-Tablet-With-Hands-Of.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49341564/why-are-shares-of-atossa-therapeutics-up-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49341564/why-are-shares-of-atossa-therapeutics-up-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4551","BK4079","Z","BK4585","BK4539","BK4139","ATOS","BK4007","BK4588","BK4548","LENZ"],"gpt_icon":0},{"id":"2590516876","title":"FDA Grants Rare Pediatric Disease Designation to Atossa Therapeutics' (Z)-Endoxifen for Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516876","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516876?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:01","pubTimestamp":1765458117,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. has received Rare Pediatric Disease  designation from the U.S. Food and Drug Administration  for its drug candidate -Endoxifen for the treatment of Duchenne Muscular Dystrophy . This regulatory milestone may qualify Atossa for a Priority Review Voucher upon future approval, which could be used for expedited FDA review of another application or sold to another company. The designation recognizes -Endoxifen's potential as a treatment for DMD, a severe childhood neuromuscular disease, and highlights its differentiated mechanism that does not target specific exon defects, potentially broadening its applicability among patients. No other organizations were mentioned as recipients of this regulatory designation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL904ncn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atossatherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0571},{"period":"1month","weight":-0.5888},{"period":"3month","weight":-0.6576},{"period":"6month","weight":-0.6533},{"period":"1year","weight":-0.668},{"period":"ytd","weight":-0.5525}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.269844},{"month":2,"riseRate":0.5,"avgChangeRate":0.054174},{"month":3,"riseRate":0.384615,"avgChangeRate":0.084638},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.043139},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.014461},{"month":6,"riseRate":0.615385,"avgChangeRate":0.128869},{"month":7,"riseRate":0.230769,"avgChangeRate":-0.109234},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.058495},{"month":9,"riseRate":0.307692,"avgChangeRate":-0.023021},{"month":10,"riseRate":0.153846,"avgChangeRate":-0.183809},{"month":11,"riseRate":0.307692,"avgChangeRate":-0.054625},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.125403}],"exchange":"NASDAQ","name":"Atossa Genetics","nameEN":"Atossa Genetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Atossa Genetics,ATOS,Atossa Genetics股票,Atossa Genetics股票老虎,Atossa Genetics股票老虎国际,Atossa Genetics行情,Atossa Genetics股票行情,Atossa Genetics股价,Atossa Genetics股市,Atossa Genetics股票价格,Atossa Genetics股票交易,Atossa Genetics股票购买,Atossa Genetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}